NEWCaplight raises a $16M Series A, led by BlackRock and Fin Capital →
Skip to main content
Caplight Logo









Netris Pharma

Netris Pharma

Private
LyonHealthcare & Life Scienceshttps://www.netrispharma.com/

Last Round

Grant

May 28, 2026

Total Funding Raised

$48.64M

Momentum

Top 5%

of companies Caplight tracks

Company Overview

Netris Pharma is a biotechnology company that develops anti-cancer therapeutic molecules designed to overcome resistance to oncology treatments.

Sector

Healthcare & Life Sciences

Verticals

Biotechnology, Clinical Trials, Drug Discovery, Precision Medicine

Business Model

B2B

Customer Profile

Services & Consulting

AI Layer

Non-AI

Keywords

biopharmaceuticaloncologymonoclonal antibodycancer therapynetrin-1clinical-stage biotechdrug resistancesolid tumorsclinical trialsepithelial-to-mesenchymal transitionEMTcancer drug discoveryprecision medicineimmuno-oncologybiotech startup

Historical Pricing

Historical view of private secondary pricing and transaction trends.

Unlock Pricing Charts

Sign up to view complete historical pricing and secondary transactions.

Caplight Momentum Score

Proprietary index based on bid/ask volume and sentiment.

View Momentum History

Track how buyer interest and sentiment changes over time.

Netris Pharma Comparables

Compare Netris Pharma with similar companies based on industry and business-model similarity.

Netris Pharma comparables — related companies by embedding similarity
CompanySimilarityMarket Cap
Medannex Ltd
81%
Compugen Ltd.
78%
Alethia Biotherapeutics
77%

Netris Pharma Funding Rounds

Historical fundraising activity

Data table
RoundDateAmount RaisedValuationInvestorsSources
GrantMay 28, 2026
Series A ExtensionDec 19, 2023
GrantJan 19, 2023
GrantDec 16, 2021
Series ADec 23, 2020

Netris Pharma Investors

Notable investors and investment history

Netris Pharma investors
InvestorRounds
European Innovation Council FundGrant
Eclosion VenturesSeries A
Eurostars SME programmeGrant
Wille Finance AGSeries A
Horizon EuropeGrant
BpifranceSeries A
EIC FundSeries A Extension

Market signals

Structured signals derived from secondary market and firmographic data.

  • Jun 21, 2026

    Monthly visitors increased 33% MoM.

Netris Pharma Filings

SEC and related filings with document metadata.

Data table
TypedDateAmount OfferedAmount SoldFillingPagesDownload
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation

Netris Pharma Filings

SEC and related filings with document metadata.

Frequently Asked Questions

Common questions about Netris Pharma's valuation, stock price, and market status.

Firmographic Details

HeadquartersLyon
Employee Range20
Year Founded2008
Last FundingMay 28, 2026

Institutional Data Access

Join leading institutional investors using Caplight to access private market data, discover pricing, and execute secondary block trades.

Requires verified institutional or accredited status.